CAMBRIDGE, Mass., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced that, on January 2, 2013, Aegerion granted stock options to purchase an aggregate of 55,000 shares of common stock to five new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $27.24, the closing price of Aegerion’s common stock on the grant date, vests in equal monthly installments over four years, has a ten year term and will be subject to the terms and conditions of a stock option agreement covering the grant.
